10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2010 | |||
Consolidated Statement of Income | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011) | |||
(In Millions, except shares in actual) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
Sales | $ 45,987 | 27,428 | 23,850 |
Costs, Expenses and Other | |||
Materials and production | 18,396 | 9,019 | 5,583 |
Marketing and administrative | 13,245 | 8,543 | 7,377 |
Research and development | 10,991 | 5,845 | 4,805 |
Restructuring costs | 985 | 1,634 | 1,033 |
Equity income from affiliates | (587) | (2,235) | (2,561) |
Other (income) expense, net | 1,304 | (10,668) | (2,318) |
Total Costs, Expenses and Other | 44,334 | 12,138 | 13,919 |
Income Before Taxes | 1,653 | 15,290 | 9,931 |
Taxes on Income | 671 | 2,268 | 1,999 |
Net Income | 982 | 13,022 | 7,932 |
Less: Net Income Attributable to Noncontrolling Interests | 121 | 123 | 124 |
Net Income Attributable to Merck & Co., Inc. | 861 | 12,899 | 7,808 |
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | 0.28 | 5.67 | 3.65 |
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | 0.28 | 5.65 | 3.63 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2010 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011) | |||
(In Millions, except shares in actual) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
Cash Flows from Operating Activities | |||
Net income | $ 982 | 13,022 | 7,932 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 7,381 | 2,576 | 1,631 |
In-process research and development impairment charges | 2,441 | ||
Gains on distributions from AstraZeneca LP | (443) | (2,223) | |
Gain related to Merck/Schering-Plough partnership | (7,530) | ||
Gain on disposition of interest in Merial Limited | (3,163) | ||
Equity income from affiliates | (587) | (2,235) | (2,561) |
Dividends and distributions from equity affiliates | 324 | 1,724 | 4,290 |
Deferred income taxes | (1,092) | 1,821 | 530 |
Share-based compensation | 509 | 415 | 348 |
Other | 377 | (535) | 608 |
Net changes in assets and liabilities: | |||
Accounts receivable | (1,089) | 165 | (889) |
Inventories | 1,990 | 1,211 | (452) |
Trade accounts payable | 124 | (45) | |
Accrued and other current liabilities | 35 | (4,003) | (1,711) |
Income taxes payable | 128 | (365) | (465) |
Noncurrent liabilities | (98) | 231 | (108) |
Other | (160) | 103 | (358) |
Net Cash Provided by Operating Activities | 10,822 | 3,392 | 6,572 |
Cash Flows from Investing Activities | |||
Capital expenditures | (1,678) | (1,461) | (1,298) |
Purchases of securities and other investments | (7,197) | (3,071) | (11,967) |
Proceeds from sales of securities and other investments | 4,561 | 10,942 | 11,066 |
Proceeds from sale of interest in Merial Limited | 4,000 | ||
Schering-Plough merger, net of cash acquired | (12,843) | ||
Acquisitions of businesses, net of cash acquired | (256) | (130) | |
Distributions from AstraZeneca LP | 647 | 1,899 | |
Decrease (Increase) in restricted assets | 276 | 5,548 | (1,630) |
Other | 150 | 171 | 96 |
Net Cash (Used in) Provided by Investing Activities | (3,497) | 3,156 | (1,834) |
Cash Flows from Financing Activities | |||
Net change in short-term borrowings | 90 | (2,422) | 1,860 |
Proceeds from issuance of debt | 1,999 | 4,228 | |
Payments on debt | (1,341) | (25) | (1,392) |
Purchases of treasury stock | (1,593) | (2,725) | |
Dividends paid to stockholders | (4,734) | (3,215) | (3,279) |
Other dividends paid | (119) | (264) | (122) |
Proceeds from exercise of stock options | 363 | 186 | 102 |
Other | (106) | (126) | 33 |
Net Cash Used in Financing Activities | (5,441) | (1,638) | (5,523) |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | (295) | 33 | (183) |
Net Increase (Decrease) in Cash and Cash Equivalents | 1,589 | 4,943 | (968) |
Cash and Cash Equivalents at Beginning of Year | 9,311 | 4,368 | |
Cash and Cash Equivalents at End of Year | 10,900 | 9,311 | 4,368 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
MERCK & CO., INC. | ||
Ticker: MRK Fiscal Year: 2010 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011) | ||
(In Millions, except shares in actual) | ||
As of | As of | |
Dec 31, 2010 | Dec 31, 2009 | |
Assets | ||
Current Assets | ||
Cash and cash equivalents | $ 10,900 | 9,311 |
Short-term investments | 1,301 | 293 |
Accounts receivable (net of allowance for doubtful accounts of $104 in 2010 and $113 in 2009) | 7,344 | 6,603 |
Inventories (excludes inventories of $1,194 in 2010 and $1,157 in 2009 classified in Other assets - see Note 8) | 5,868 | 8,048 |
Deferred income taxes and other current assets | 3,651 | 4,177 |
Total current assets | 29,064 | 28,432 |
Investments | 2,175 | 432 |
Property, Plant and Equipment (at cost) | ||
Land | 658 | 667 |
Buildings | 11,945 | 12,231 |
Machinery, equipment and office furnishings | 15,894 | 16,158 |
Construction in progress | 2,066 | 1,818 |
Property, Plant and Equipment, Gross | 30,563 | 30,874 |
Less allowance for depreciation | 13,481 | 12,595 |
Property, Plant and Equipment, Net | 17,082 | 18,279 |
Goodwill | 12,378 | 12,038 |
Other Intangibles, Net | 39,456 | 47,757 |
Other Assets | 5,626 | 5,376 |
Total Assets | 105,781 | 112,314 |
Liabilities and Equity | ||
Current Liabilities | ||
Loans payable and current portion of long-term debt | 2,400 | 1,379 |
Trade accounts payable | 2,308 | 2,244 |
Accrued and other current liabilities | 8,514 | 9,455 |
Income taxes payable | 1,243 | 1,167 |
Dividends payable | 1,176 | 1,189 |
6% Mandatory convertible preferred stock, $1 par value Authorized - 11,500,000 shares issued and outstanding - 855,422 shares | 0 | 207 |
Total current liabilities | 15,641 | 15,641 |
Long-Term Debt | 15,482 | 16,095 |
Deferred Income Taxes and Noncurrent Liabilities | 17,853 | 19,093 |
Merck & Co., Inc. Stockholders' Equity | ||
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,576,948,356 shares - 2010; 3,562,528,536 - 2009 | 1,788 | 1,781 |
Other paid-in capital | 40,701 | 39,683 |
Retained earnings | 37,536 | 41,405 |
Accumulated other comprehensive loss | (3,216) | (2,767) |
Stockholders' equity before deduction for treasury stock | 76,809 | 80,102 |
Less treasury stock, at cost: 494,841,533 shares - 2010; 454,305,985 shares - 2009 | 22,433 | 21,044 |
Total Merck & Co., Inc. stockholders' equity | 54,376 | 59,058 |
Noncontrolling Interests | 2,429 | 2,427 |
Total equity | 56,805 | 61,485 |
Total Liabilities and Stockholders' Equity | 105,781 | 112,314 |
External Links | |
MERCK & CO., INC. (MRK) Fiscal Year 2010 | |
Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |